Life Sciences
Haynes and Boone’s Life Sciences Practice Group has robust experience in medical and surgical devices, drug delivery, biotechnology and biosimilar arts, Food and Drug Administration law and regulations, and intellectual property. We represent a wide array of emerging growth, middle stage and Fortune 100 companies in the biotechnology, consumer medical products and medical technology industries, and have a knowledge base and skillset that is particularly helpful to our clients in this field. Our practitioners represent clients in technology areas, such as:
- Drug delivery devices including implants, transdermal patches, and injectable devices; drug modeling and prediction
- Polymer and coatings chemistry, including modified release, immediate release, and disintegrating formulations, biodegradable polymers, enteric coatings, bioresorbable polymers, expanded porphyrin and pyrrole macrocycles, and chemical processes
- Genetic engineering, transgenic organisms, genomics, gene therapy, proteomics, plant molecular biology, transgenic plants, disease resistance; microbiology, immunology including vaccine and antibody technology, and endocrinology
- Medical equipment, imaging methods, photodynamic therapy, cardiovascular devices, ophthalmologic diagnostics and treatment, spinal fixation implants and associated surgical methods, general orthopedic implants and total joint replacements, stents, catheters, and a variety of other medical and dental prosthetic devices with related surgical methods
Haynes and Boone, LLP Life Sciences Partner Vincent Shier was featured in the most recent issue of Alt-Meat magazine, discussing the benefits of patents for companies producing plant-based foods. Read an excerpt below. In 2023, one company – Impossible Foods – held more than half of the plant-based, meat-related patents in both the U.S. and E.U., according to a Stanford University Investigation. [...]
Intellectual Property Partner Jeff Morton Joins Haynes Boone in Southern California
May 13, 2024
